Human adrenal tumors are difficult to study, in part, due to the absence of cultured cell lines that faithfully represent adrenal cells in the early stages of transformation. To fill this void, we have developed two novel Human Adrenocortical Adenoma (HAA) cell lines (HAA1 & HAA2). These HAA1/2 cell lines are unique in their ability to exit a non-functional state and undergo differentiation. Specifically, our group is interested in studying ways to help induce expression steroidogenic enzymes upon treatment with histone deacetylase (HDAC) inhibitors. With further studies, we are working on finding new factors that can regulate steroidogenic expression in adrenal tumors.
Dr. Kenneth Cusi presented for the OneFlorida Obesity Workgroup
May 11, 2017
Nonalcoholic Fatty Liver Disease (NAFLD): The Overlooked Complication of T2DM
About the OneFlorida Clinical Research Consortium
The OneFlorida Clinical Research Consortium’s Commitment to Community-based Pragmatic Clinical Trials and Implementation Science
Traditional clinical research has focused heavily on determining the efficacy of interventions, and clinical guidelines have been developed to guide health care providers based on these results. Unfortunately, these studies are often carried out in atypical settings, such as large academic health centers with a restricted patient population and intensive human and financial resource support. This type of scenario is often quite different from what community health care providers experience at their practices—where resources are limited, the patient population is heterogeneous and patients have limited means to proceed with recommended changes or referrals. Thus, the success of many promising interventions is highly variable and most often minimized at the local, community-practice level.
The OneFlorida Clinical Research Consortium, which is led by the University of Florida Clinical and Translational Research Institute and includes the University of Florida, Florida State University and the University of Miami, was developed to address the need for research and support to translate the evidence-base gained in these “atypical” academic environments to the community practices of Florida. Its central aim is to facilitate a multi-way exchange of information between academic health research teams, community practices and patients and thereby accelerate the translation of health care research findings to diverse health care settings across the state. OneFlorida partners encompass 22 hospitals, 416 clinic settings and 3,250 physician providers, which provide care for more than 10 million patients across Florida’s 67 counties. Together, OneFlorida partners cover 39 percent of the patient population in what will soon be the nation’s third largest state, including three majority-minority metropolitan areas (Jacksonville, Orlando and Miami) and rural practices throughout the state.